Koido Shigeo, Homma Sadamu, Takahara Akitaka, Namiki Yoshihisa, Tsukinaga Shintaro, Mitobe Jimi, Odahara Shunichi, Yukawa Toyokazu, Matsudaira Hiroshi, Nagatsuma Keisuke, Uchiyama Kan, Satoh Kenichi, Ito Masaki, Komita Hideo, Arakawa Hiroshi, Ohkusa Toshifumi, Gong Jianlin, Tajiri Hisao
Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Clin Dev Immunol. 2011;2011:267539. doi: 10.1155/2011/267539. Epub 2011 Sep 14.
Pancreatic cancer is a highly aggressive and notoriously difficult to treat. As the vast majority of patients are diagnosed at advanced stage of the disease, only a small population is curative by surgical resection. Although gemcitabine-based chemotherapy is typically offered as standard of care, most patients do not survive longer than 6 months. Thus, new therapeutic approaches are needed. Pancreatic cancer cells that develop gemcitabine resistance would still be suitable targets for immunotherapy. Therefore, one promising treatment approach may be immunotherapy that is designed to target pancreatic-cancer-associated antigens. In this paper, we detail recent work in immunotherapy and the advances in concept of combination therapy of immunotherapy and chemotherapy. We offer our perspective on how to increase the clinical efficacy of immunotherapies for pancreatic cancer.
胰腺癌具有高度侵袭性，且治疗难度极大。由于绝大多数患者在疾病晚期才被诊断出来，只有一小部分患者能够通过手术切除治愈。尽管以吉西他滨为基础的化疗通常作为标准治疗方案，但大多数患者的生存期不超过6个月。因此，需要新的治疗方法。产生吉西他滨耐药性的胰腺癌细胞仍可能是免疫治疗的合适靶点。因此，一种有前景的治疗方法可能是旨在靶向胰腺癌相关抗原的免疫治疗。在本文中，我们详细介绍了免疫治疗的最新研究工作以及免疫治疗与化疗联合治疗概念的进展。我们就如何提高胰腺癌免疫治疗的临床疗效提出了自己的观点。
